Compare VFF & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | ADAG |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.9M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | VFF | ADAG |
|---|---|---|
| Price | $3.68 | $1.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.1M | 49.9K |
| Earning Date | 11-10-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $351,979,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $6.54 | $36.05 |
| P/E Ratio | $74.00 | ★ N/A |
| Revenue Growth | ★ 56.61 | N/A |
| 52 Week Low | $0.45 | $1.30 |
| 52 Week High | $4.99 | $3.16 |
| Indicator | VFF | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 49.51 |
| Support Level | $3.56 | $1.74 |
| Resistance Level | $3.95 | $1.90 |
| Average True Range (ATR) | 0.38 | 0.12 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 11.15 | 71.88 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.